This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig 2CV v3.1 was used to generate the results found in this report.
-
Working with individual set: LUSC-TP
-
Number of patients in set: 178
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:LUSC-TP.final_analysis_set.maf
-
Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt
-
Significantly mutated genes (q ≤ 0.1): 16
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Column Descriptions:
-
nnon = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | gene | longname | codelen | nnei | nncd | nsil | nmis | nstp | nspl | nind | nnon | npat | nsite | pCV | pCL | pFN | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | TP53 | tumor protein p53 | 1890 | 25 | 0 | 1 | 96 | 20 | 17 | 17 | 150 | 145 | 97 | 1e-16 | 1e-05 | 1e-05 | 1e-16 | 9.1e-13 |
2 | CDKN2A | cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) | 1002 | 1 | 0 | 1 | 11 | 8 | 3 | 4 | 26 | 26 | 23 | 2.1e-15 | 0.43 | 1e-05 | 1e-16 | 9.1e-13 |
3 | NFE2L2 | nuclear factor (erythroid-derived 2)-like 2 | 1834 | 18 | 0 | 0 | 27 | 0 | 0 | 1 | 28 | 27 | 15 | 8.7e-13 | 1e-05 | 1e-05 | 3.3e-16 | 2e-12 |
4 | MLL2 | myeloid/lymphoid or mixed-lineage leukemia 2 | 16826 | 1 | 0 | 4 | 21 | 12 | 6 | 3 | 42 | 36 | 42 | 1.3e-13 | 1 | 0.41 | 2.8e-12 | 1.3e-08 |
5 | KEAP1 | kelch-like ECH-associated protein 1 | 1895 | 30 | 0 | 0 | 22 | 1 | 0 | 1 | 24 | 22 | 21 | 5.6e-12 | 0.064 | 0.19 | 1e-11 | 3.6e-08 |
6 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 1244 | 34 | 0 | 0 | 8 | 6 | 0 | 2 | 16 | 14 | 15 | 6.3e-12 | 0.087 | 0.48 | 2.5e-11 | 7.7e-08 |
7 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 3287 | 16 | 0 | 1 | 28 | 0 | 1 | 0 | 29 | 27 | 16 | 5.7e-06 | 1e-05 | 0.0037 | 1.4e-09 | 3.6e-06 |
8 | RB1 | retinoblastoma 1 (including osteosarcoma) | 3713 | 14 | 0 | 0 | 2 | 2 | 5 | 3 | 12 | 12 | 12 | 2.9e-10 | 1 | 0.77 | 6.6e-09 | 0.000015 |
9 | CYP11B1 | cytochrome P450, family 11, subfamily B, polypeptide 1 | 1546 | 24 | 0 | 0 | 15 | 0 | 0 | 0 | 15 | 15 | 15 | 7e-08 | 1 | 0.93 | 1.2e-06 | 0.0025 |
10 | NOTCH1 | Notch homolog 1, translocation-associated (Drosophila) | 7800 | 16 | 0 | 3 | 8 | 6 | 1 | 1 | 16 | 14 | 16 | 2.2e-06 | 1 | 0.0082 | 1.6e-06 | 0.003 |
11 | ASB5 | ankyrin repeat and SOCS box-containing 5 | 1016 | 14 | 0 | 0 | 8 | 0 | 1 | 0 | 9 | 9 | 9 | 0.000038 | 1 | 0.0079 | 1e-05 | 0.017 |
12 | IRF6 | interferon regulatory factor 6 | 1432 | 18 | 0 | 0 | 3 | 2 | 1 | 0 | 6 | 6 | 6 | 0.000017 | 0.066 | 0.95 | 0.000019 | 0.029 |
13 | EP300 | E1A binding protein p300 | 7365 | 7 | 0 | 2 | 8 | 0 | 1 | 0 | 9 | 8 | 8 | 0.17 | 0.00012 | 0.19 | 0.000024 | 0.034 |
14 | CPS1 | carbamoyl-phosphate synthetase 1, mitochondrial | 4748 | 23 | 1 | 2 | 26 | 0 | 2 | 0 | 28 | 24 | 27 | 7.6e-06 | 0.27 | 0.75 | 0.000033 | 0.043 |
15 | ARID1A | AT rich interactive domain 1A (SWI-like) | 6934 | 1 | 0 | 2 | 7 | 1 | 2 | 4 | 14 | 13 | 14 | 5.2e-06 | 1 | 0.93 | 0.000068 | 0.083 |
16 | SLC28A1 | solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 | 2087 | 29 | 0 | 1 | 5 | 1 | 3 | 0 | 9 | 9 | 9 | 0.000064 | 1 | 0.033 | 0.000086 | 0.098 |
17 | POLR2B | polymerase (RNA) II (DNA directed) polypeptide B, 140kDa | 4561 | 26 | 0 | 0 | 3 | 1 | 2 | 0 | 6 | 6 | 6 | 0.000011 | 1 | 0.97 | 0.00014 | 0.15 |
18 | HRAS | v-Ha-ras Harvey rat sarcoma viral oncogene homolog | 659 | 570 | 0 | 0 | 5 | 0 | 0 | 0 | 5 | 5 | 4 | 0.053 | 0.0016 | 0.043 | 0.00015 | 0.15 |
19 | PI16 | peptidase inhibitor 16 | 1416 | 89 | 0 | 1 | 5 | 1 | 1 | 0 | 7 | 7 | 7 | 0.00018 | 1 | 0.073 | 0.00034 | 0.33 |
20 | EGFR | epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) | 3999 | 35 | 0 | 1 | 6 | 0 | 1 | 0 | 7 | 6 | 6 | 0.34 | 0.012 | 0.004 | 0.00038 | 0.33 |
21 | TAF2 | TAF2 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 150kDa | 3810 | 7 | 0 | 1 | 7 | 2 | 1 | 0 | 10 | 9 | 10 | 0.000067 | 1 | 0.37 | 0.00038 | 0.33 |
22 | PDZD7 | PDZ domain containing 7 | 1586 | 18 | 0 | 0 | 3 | 0 | 1 | 0 | 4 | 4 | 3 | 0.0015 | 0.023 | 0.14 | 0.00041 | 0.34 |
23 | HLA-A | major histocompatibility complex, class I, A | 1128 | 217 | 0 | 0 | 1 | 4 | 2 | 0 | 7 | 6 | 7 | 0.0032 | 1 | 0.0038 | 0.00045 | 0.36 |
24 | SGK223 | 4225 | 2 | 0 | 0 | 3 | 0 | 1 | 2 | 6 | 6 | 6 | 0.0001 | 1 | 0.43 | 0.00052 | 0.39 | |
25 | FAT1 | FAT tumor suppressor homolog 1 (Drosophila) | 13871 | 23 | 0 | 8 | 13 | 11 | 1 | 0 | 25 | 21 | 24 | 0.00025 | 0.19 | 0.87 | 0.00055 | 0.39 |
26 | REG1B | regenerating islet-derived 1 beta (pancreatic stone protein, pancreatic thread protein) | 521 | 6 | 0 | 1 | 8 | 2 | 1 | 0 | 11 | 11 | 9 | 0.0067 | 0.0034 | 0.24 | 0.00056 | 0.39 |
27 | AKAP11 | A kinase (PRKA) anchor protein 11 | 5750 | 0 | 0 | 0 | 3 | 2 | 2 | 0 | 7 | 7 | 7 | 0.000055 | 1 | 0.82 | 0.00059 | 0.4 |
28 | IBTK | inhibitor of Bruton agammaglobulinemia tyrosine kinase | 4170 | 3 | 0 | 0 | 3 | 1 | 2 | 0 | 6 | 5 | 6 | 0.014 | 0.013 | 0.17 | 0.00062 | 0.4 |
29 | DHTKD1 | dehydrogenase E1 and transketolase domain containing 1 | 2826 | 0 | 0 | 0 | 4 | 2 | 1 | 0 | 7 | 7 | 6 | 0.0027 | 0.037 | 0.4 | 0.00063 | 0.4 |
30 | ABI3BP | ABI gene family, member 3 (NESH) binding protein | 3366 | 13 | 0 | 1 | 5 | 3 | 2 | 0 | 10 | 9 | 10 | 0.0003 | 1 | 0.081 | 0.00067 | 0.41 |
31 | MUC5B | mucin 5B, oligomeric mucus/gel-forming | 17492 | 36 | 0 | 8 | 29 | 2 | 2 | 1 | 34 | 29 | 34 | 0.000085 | 1 | 0.56 | 0.00088 | 0.52 |
32 | CCDC83 | coiled-coil domain containing 83 | 1379 | 13 | 0 | 0 | 5 | 1 | 1 | 0 | 7 | 6 | 7 | 0.00019 | 1 | 0.43 | 0.0011 | 0.64 |
33 | KDM6A | lysine (K)-specific demethylase 6A | 4318 | 7 | 0 | 0 | 1 | 2 | 4 | 0 | 7 | 7 | 7 | 0.0013 | 0.16 | 0.24 | 0.0013 | 0.71 |
34 | COL7A1 | collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive) | 9304 | 10 | 0 | 2 | 8 | 3 | 1 | 1 | 13 | 13 | 13 | 0.00093 | 1 | 0.1 | 0.0013 | 0.71 |
35 | CUL3 | cullin 3 | 2367 | 69 | 0 | 1 | 6 | 2 | 4 | 0 | 12 | 11 | 12 | 0.0007 | 0.18 | 0.87 | 0.0014 | 0.75 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.